Company intelligence / Profile preview
TR Therapeutics
Reston, Virginia, United Statestrtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TR Therapeutics is a clinical-stage biopharmaceutical company developing advanced wound healing products. Its lead candidate, TR‑987, is a topical agent targeting TLR2 for the treatment of varicose ulcers and chronic wounds. The drug has completed Phase II trials showing safety and efficacy in aesthetic dermatology, with ongoing Phase III trials for varicose ulcers in the US. Results from earlier studies indicated significant improvement in skin quality compared to placebo.
- Therapeutic areas
- OtherCardiovascular
- Modalities
- Small moleculeGlucan-based biologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on TR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TR Therapeutics.